Drug intelligence / Profile preview

MTI-201

Development stage: Phase 1
Lead developer: Modulation Therapeutics
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

MTI-201 is an investigational radioligand therapy developed for the treatment of metastatic uveal melanoma and cutaneous melanoma. It consists of a cyclic beta-hairpin peptidomimetic that targets the melanocortin 1 receptor (MC1R), which is highly expressed in melanoma cells. The drug delivers a cytotoxic payload of Actinium 225, an alpha particle-emitting radionuclide, directly to MC1R-expressing tumor cells, resulting in targeted cell destruction while minimizing damage to healthy tissues. MTI-201 is administered intravenously and is currently in Phase I clinical trials for metastatic uveal melanoma[1][3][4][5].

Other names: actinium Ac 225-DOTA-MTI-201225Ac-MTI-201

Targets

MC1R (Melanocortin Type 1 Receptor)

Beyond the preview

Go deeper on MTI-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTI-201.

Explore the full profile